PD-1 antibody cemiplimab demonstrates 46.3% ORR in advanced cutaneous squamous cell carcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A pivotal phase II clinical study of cemiplimab, an investigational human antibody targeting PD-1, demonstrated an overall response rate of 46.3% in 82 patients with advanced cutaneous squamous cell carcinoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Login